NCT05711524View on ClinicalTrials.gov

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

October 23, 2024

Study Completion Date

September 30, 2025

Conditions
HypofibrinogenemiaBleeding
Interventions
BIOLOGICAL

Traditional Cryoprecipitate

This is the cryoprecipitate already currently being given to patients with a cryo order.

BIOLOGICAL

Pathogen-Reduced Cryoprecipitate

This is the pathogen-reduced cryoprecipitate that is intended to be compared to the standard cryoprecipitate.

Trial Locations (1)

10065

New York-Presbyterian Hospital/Weill Cornell Medical Center, New York

Sponsors

Collaborators (1)

Cerus Corporation
All Listed Sponsors
collaborator

Cerus Corporation

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT05711524 - Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding | Biotech Hunter | Biotech Hunter